Cargando…

Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study

This study was designed to observe the efficacy and safety of albumin-bound paclitaxel plus nedaplatin as neoadjuvant therapy in patients with esophageal squamous cell carcinoma (ESCC). From April 2019 to Dec 2020, patients with ESCC who underwent Mckeown surgery at our center were analyzed retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jiakuan, Zhu, Jianfei, Zhang, Yan, Wang, Wenchen, Xia, Yanmin, Zhao, Jinbo, Jiang, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981396/ https://www.ncbi.nlm.nih.gov/pubmed/36862884 http://dx.doi.org/10.1097/MD.0000000000033157

Ejemplares similares

Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
por: Qiu, Xiangnan, et al.
Publicado: (2020)

Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study
por: Oi, Hajime, et al.
Publicado: (2022)

Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma
por: Xu, Hongyan, et al.
Publicado: (2022)

Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis
por: Naito, Yujiro, et al.
Publicado: (2017)

First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma: A case series and review of the literature
por: Kong, Feng-Wei, et al.
Publicado: (2020)

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
por: Anzai, Masaki, et al.
Publicado: (2017)

Efficacy and toxicity of three concurrent chemoradiotherapy regimens in treating nasopharyngeal carcinoma: Comparison among cisplatin, nedaplatin, and lobaplatin
por: Liang, Xuexia, et al.
Publicado: (2022)

Factors Associated With False-Negative Endoscopic Biopsy Results After Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
por: Chao, Yin-Kai, et al.
Publicado: (2015)

A single-arm, multicenter, phase II clinical study of tislelizumab plus albumin-bound paclitaxel/cisplatin as neoadjuvant therapy for borderline resectable esophageal squamous cell carcinoma
por: Li, Xiaodong, et al.
Publicado: (2022)

Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
por: Hassan, Md Sazzad, et al.
Publicado: (2018)

Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience
por: Ding, Wei, et al.
Publicado: (2020)

Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study
por: Sugiyama, Keiji, et al.
Publicado: (2019)

Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Shi, Yan, et al.
Publicado: (2013)

Neoadjuvant chemotherapy with paclitaxel plus cisplatin before radical surgery for locally advanced cervical cancer during pregnancy: A case series and literature review
por: Huang, Huiqiong, et al.
Publicado: (2021)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
por: Wang, Huan, et al.
Publicado: (2022)

Lymphopenia Predicts Poor Prognosis in Patients With Esophageal Squamous Cell Carcinoma
por: Feng, Ji-Feng, et al.
Publicado: (2014)

Second primary malignancy in patients with esophageal adenocarcinoma and squamous cell carcinoma
por: Zhang, Guoqing, et al.
Publicado: (2019)

High expression of PDGFA predicts poor prognosis of esophageal squamous cell carcinoma
por: Han, Na, et al.
Publicado: (2021)

Expression and prognostic value of AIM1L in esophageal squamous cell carcinoma
por: Zhou, Lu, et al.
Publicado: (2023)

Pembrolizumab versus paclitaxel for previously treated, advanced gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized clinical trials
por: Swed, Sarya, et al.
Publicado: (2022)

Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan
por: Chen, Hui-Shan, et al.
Publicado: (2016)

Expression of SIRT1 and survivin correlates with poor prognosis in esophageal squamous cell carcinoma
por: Yan, Li, et al.
Publicado: (2020)

High FN1 expression is associated with poor survival in esophageal squamous cell carcinoma
por: Ma, Junliang, et al.
Publicado: (2022)

Real-world treatment patterns and survival for locally advanced esophageal squamous cell carcinoma
por: Luo, Hua-Chun, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study
por: Ohnuma, Hiroyuki, et al.
Publicado: (2018)

Circulating uPA as a potential prognostic biomarker for resectable esophageal squamous cell carcinoma
por: He, Xiao, et al.
Publicado: (2019)

A nomogram based on hematological markers to predict radiosensitivity in patients with esophageal squamous cell carcinoma
por: Sun, Lijun, et al.
Publicado: (2023)

Correlation Between Tumor Regression Grade and Clinicopathological Parameters in Patients With Squamous Cell Carcinoma of the Esophagus Who Received Neoadjuvant Chemoradiotherapy
por: Chao, Yin-Kai, et al.
Publicado: (2015)

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
por: Sekine, I, et al.
Publicado: (2004)

High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma
por: Oh, Dongryul, et al.
Publicado: (2016)

Microvessel density as a prognostic factor in esophageal squamous cell cancer patients: A meta-analysis
por: Ma, Guangzhi, et al.
Publicado: (2017)

High expression of cytokeratin CAM5.2 in esophageal squamous cell carcinoma is associated with poor prognosis
por: He, Shujin, et al.
Publicado: (2019)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

Common gene signatures and key pathways in hypopharyngeal and esophageal squamous cell carcinoma: Evidence from bioinformatic analysis
por: Zhou, Rui, et al.
Publicado: (2020)

The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma
por: Bao, Junhui, et al.
Publicado: (2020)

Prognostic value of neutrophil-to-lymphocyte ratio in peripheral blood and pathological tissue in patients with esophageal squamous cell carcinoma
por: Guo, Quanquan, et al.
Publicado: (2020)

Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis
por: Zong, Yu, et al.
Publicado: (2017)

Remnant lymph node metastases after neoadjuvant therapy and surgery in patients with pathologic T0 esophageal carcinoma impact on prognosis: A systematic review and meta-analysis
por: Lv, Hong-Wei, et al.
Publicado: (2017)

A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient: A case report
por: Fang, Yueyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hhv343ckkct13i0g5j1or66mru